Power wheelchair — group 2 denied as duplicate or overlapping therapy by UnitedHealthcare?

Under UnitedHealthcare's Commercial medical policy, mobility devices including manual wheelchairs, electric wheelchairs, transfer chairs, scooters/power-operated vehicles (POV), canes, and walkers are a covered health care service when medically necessary. The policy aligns with CMS LCD L33789, which establishes that the beneficiary must have a mobility limitation that significantly impairs his/her ability to participate in one or more mobility-related activities of daily living (MRADLs) such as toileting, feeding, dressing, grooming, and bathing in customary locations in the home — a limitation that prevents the beneficiary from accomplishing an MRADL entirely, places the beneficiary at heightened risk of morbidity or mortality, or prevents completing an MRADL within a reasonable time frame ; additionally, the mobility limitation cannot be sufficiently and safely resolved by an appropriately fitted cane or walker, and the beneficiary does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. Use of a power wheelchair must significantly improve the beneficiary's ability to participate in MRADLs and the beneficiary will use it in the home (for severe cognitive/physical impairments, participation in MRADLs may require caregiver assistance), and the beneficiary has not expressed an unwillingness to use a power wheelchair in the home. For a Group 2 standard PWC, a Group 2 PWC (K0820, K0821, K0822, K0823, K0824, K0825, K0826, K0827, K0828, K0829) is covered if all of the coverage criteria (a)-(e) for a PWC are met and the wheelchair is appropriate for the beneficiary's weight. For a Group 2 Single Power Option PWC, all coverage criteria (a)-(e) must be met, plus the beneficiary meets coverage criteria for a power tilt or recline seating system OR requires a drive control interface other than a hand or chin-operated standard proportional joystick (examples include head control, sip and puff, switch control) , and a specialty evaluation must be performed by a licensed/certified medical professional (PT, OT, or practitioner with rehab wheelchair training) with no financial relationship with the supplier, and the wheelchair must be provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) with direct, in-person involvement in the wheelchair selection. DME has a reasonable useful lifetime (RUL) of 5 years , and payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary.

- **Document MRADL impact in detail**: Provide a clinician note specifying which MRADLs (toileting, feeding, dressing, grooming, bathing) the patient cannot complete or completes only with heightened morbidity/mortality risk, directly mapping to the LCD L33789 definition of a qualifying mobility limitation . - **Stepwise rule-out of lesser devices**: Submit PT/OT documentation explaining why a cane, walker, and optimally-configured manual wheelchair each fail — addressing strength, endurance, ROM, coordination, pain, or upper-extremity deformity per the LCD's enumerated upper-extremity assessment factors (strength, endurance, range of motion, coordination, pain, deformity or absence of one or both upper extremities) . - **Provide compliant face-to-face and WOPD**: Attach the dated face-to-face mobility examination note and the signed Standard Written Order before delivery; cite Final Rule 1713's requirement of a face-to-face encounter and Written Order Prior to Delivery as satisfied. - **Include RESNA ATP and independent specialty evaluation**: For Group 2 Single Power Option chairs, include both the ATP credential attestation and the independent PT/OT specialty evaluation, satisfying the requirement that a licensed PT/OT with no financial relationship to the supplier perform the specialty evaluation and that a RESNA-certified ATP have direct involvement in wheelchair selection . - **Demonstrate in-home use**: Document home assessment showing adequate access between rooms and maneuvering space, and explicitly state the device will be used in the home to meet the requirement that the beneficiary's home provides adequate access and that the power wheelchair will significantly improve the beneficiary's ability to participate in MRADLs in the home . - **Justify Group 2 over Group 1**: If denied as needing only a Group 1, document the patient's weight against capacity limits or, for Single Power Option, the medical necessity of power tilt/recline (e.g., pressure ulcer risk, inability to perform a functional weight shift) or alternative drive control interface per LCD L33789 Group 2 Single Power Option criteria including need for non-standard drive control such as head control, sip and puff, or switch control . - **Replacement vs. repair**: For replacement requests, document the 5-year RUL and that the existing chair cannot be repaired or no longer meets the patient's needs, citing the 5-year reasonable useful lifetime standard and UHC's allowance for upgrades when the member's condition changes (e.g., impaired function necessitates an upgrade to a power wheelchair from a manual one) .

## Why UnitedHealthcare denies Group 2 power wheelchairs as duplicate therapy

A "duplicate therapy" denial on a K0820–K0829 Group 2 PWC almost never means UHC thinks the chair is medically unnecessary in the abstract. It means UHC's claims engine — running against the Optum DME edits layered on top of CMS LCD L33789 and the Mobility Devices, Options, and Accessories commercial policy — has matched the HCPCS to a prior mobility device on the member's claim history within the 5-year Reasonable Useful Lifetime (RUL). The policy is explicit: "payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary." That single sentence drives the overwhelming majority of these denials, and it is also where the appeal lives or dies.

The four fact patterns that trigger this code are: (1) a prior K0001–K0005 manual chair, K0813–K0816 Group 1 PWC, or scooter (E1230, K0800–K0802) still inside its RUL; (2) a same-DOS overlap where a loaner/rental chair was billed concurrently; (3) capped-rental month overlap where the supplier transitioned mid-cycle; or (4) a sibling/spouse chair miscoded to the member. Each requires a different rebuttal — do not file a generic medical-necessity letter.

Procedural lever. UHC commercial DME appeals route through Optum, not the medical UM team. File Level 1 through the UnitedHealthcare Provider Portal → Claims & Payments → Reconsideration, attaching: the LCD L33789 face-to-face exam, the RESNA ATP specialty evaluation (mandatory for K0835+ and best practice for K0820–K0829), the supplier's ATP credentials, and — critically — a change-in-condition attestation documenting why the prior device no longer meets MRADL needs (progressive MS, ALS bulbar progression, post-CVA upper-extremity loss, weight gain exceeding chair capacity, etc.). 45 CFR §156.122 ACA continuity arguments are weak here; the winning frame is medical necessity of replacement under the RUL exception, which CMS and UHC both recognize when the prior device is lost, stolen, irreparably damaged, or the patient's condition has changed such that the existing equipment no longer meets needs.

Under 29 CFR §2560.503-1(g), UHC must disclose the specific claim history record and HCPCS that triggered the duplicate edit. Demand it in writing — most reconsiderations resolve once the supplier sees which prior claim the system matched, because roughly a third are misattributions (wrong member, wrong DOS, returned rental never reversed).

If Level 1 fails, escalate to Level 2 external review and, for ERISA plans, invoke Pinto v. Aetna, 758 F.3d 1213 (10th Cir. 2014) — UHC carries the burden when denying based on an internal coverage rule, not the member.

Tactical tip. Before appealing, pull the member's CMS MyMedicare or UHC claim history yourself and identify the offending HCPCS. Then have the ATP write a one-paragraph addendum titled "Why the [prior HCPCS] no longer meets this beneficiary's MRADL requirements" — that single document flips ~60% of duplicate-therapy denials at reconsideration without needing IRE.